Royal Bank Of Canada Cidara Therapeutics, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.68 - $0.97 $4,220 - $6,019	-6,206 Reduced 96.19%	246 $0
Q3 2023 Nov 14, 2023	BUY	$0.77 - $1.16 $2,471 - $3,723	3,210 Added 99.01%	6,452 $6,000
Q2 2023 Aug 14, 2023	SELL	$1.01 - $1.42 $18,702 - $26,294	-18,517 Reduced 85.1%	3,242 $3,000
Q1 2023 May 15, 2023	BUY	$0.75 - $1.98 $16,308 - $43,053	21,744 Added 144960.0%	21,759 $27,000
Q4 2022 Feb 14, 2023	BUY	$0.48 - $0.76 $7 - $11	15 New	15 $0

Q3 2021 Nov 15, 2021	SELL	$1.48 - $2.35 $2,930 - $4,653	-1,980 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.87 - $2.7 $3,702 - $5,346	1,980 New	1,980 $4,000

22.1M

2.7K

100

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $889M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.